Skip to content

Study · Animal study (in vivo) · rat · 2018

24 results

Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide.

Makino A, Takagi H, Takahashi Y, Hase N, Sugiyama H, Yamana K, Kobayashi T

Calcified tissue international3 May 2018Cited by 36 (Europe PMC)

PMID29725706 (opens in a new tab)PMCIDPMC6105163 (opens in a new tab)DOI10.1007/s00223-018-0422-4 (opens in a new tab)PepBankPUB-29725706
Download PDFPubMedAsk about this study
Jump to 24 results

Summary

Abaloparatide (ABL) is a novel synthetic peptide analog of parathyroid hormone-related protein. In previous reports, intermittent ABL administration showed robust bone mineral density (BMD) increase and reduced the incidence of fractures in patients with osteoporosis, while its calcemic effect was reduced, as compared with teriparatide (TPTD), a parathyroid hormone N-terminal fragment. The present study aimed to elucidate the effects of ABL on bone anabolism and bone turnover as compared with TPTD. In ovariectomized (OVX) rats, ABL increased the bone strength and BMD of lumbar spine by intermittent administration similar to TPTD. Both ABL and TPTD increased the bone formation marker serum P1NP with little effect on the bone resorption maker urine DPD/Cr, suggesting anabolic effects on bone. In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment. In contrast, ABL and TPTD similarly promoted the expression of bone formation-related factors, IGF-1 and osteocalcin. In addition, there were no significant differences in the effects on WNT signaling inhibitors such as sclerostin and dickkopf-related protein 1 (DKK1) between the two peptides. These results demonstrate that ABL exerts bone anabolic effects in OVX rats. It is also indicated that ABL stimulates the expression of RANKL/OPG and M-CSF less than TPTD, while showing similar effects on bone formation-related factors and WNT signaling inhibitors in vitro. The profile of ABL indicates that it would be a suitable bone anabolic agent for osteoporosis.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study24

24 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, intermittent abaloparatide increased lumbar spine bone strength similarly to teriparatide.

    In plain wordsIn rats with removed ovaries, abaloparatide increased spinal bone strength similarly to teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeLumbar spine bone strength
    Study

    ratn: not reported in source

    Ovariectomized rats
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In ovariectomized (OVX) rats, ABL increased the bone strength and BMD of lumbar spine by intermittent administration similar to TPTD.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, intermittent teriparatide increased lumbar spine bone strength similarly to abaloparatide.

    In plain wordsIn rats with removed ovaries, teriparatide increased spinal bone strength similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLumbar spine bone strength
    Study

    ratn: not reported in source

    Ovariectomized rats
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In ovariectomized (OVX) rats, ABL increased the bone strength and BMD of lumbar spine by intermittent administration similar to TPTD.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, intermittent abaloparatide increased lumbar spine BMD similarly to teriparatide.

    In plain wordsIn rats with removed ovaries, abaloparatide increased spinal bone density similarly to teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeLumbar spine BMD
    Study

    ratn: not reported in source

    Ovariectomized rats
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In ovariectomized (OVX) rats, ABL increased the bone strength and BMD of lumbar spine by intermittent administration similar to TPTD.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, intermittent teriparatide increased lumbar spine BMD similarly to abaloparatide.

    In plain wordsIn rats with removed ovaries, teriparatide increased spinal bone density similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLumbar spine BMD
    Study

    ratn: not reported in source

    Ovariectomized rats
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In ovariectomized (OVX) rats, ABL increased the bone strength and BMD of lumbar spine by intermittent administration similar to TPTD.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, abaloparatide increased serum P1NP.

    In plain wordsIn rats with removed ovaries, abaloparatide increased a blood marker of bone formation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSerum P1NP
    Study

    ratn: not reported in source

    Ovariectomized rats
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both ABL and TPTD increased the bone formation marker serum P1NP with little effect on the bone resorption maker urine DPD/Cr, suggesting anabolic effects on bone.
    1 context sentence
    Summary · context
    In ovariectomized (OVX) rats, ABL increased the bone strength and BMD of lumbar spine by intermittent administration similar to TPTD.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, teriparatide increased serum P1NP.

    In plain wordsIn rats with removed ovaries, teriparatide increased a blood marker of bone formation.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum P1NP
    Study

    ratn: not reported in source

    Ovariectomized rats
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both ABL and TPTD increased the bone formation marker serum P1NP with little effect on the bone resorption maker urine DPD/Cr, suggesting anabolic effects on bone.
    1 context sentence
    Summary · context
    In ovariectomized (OVX) rats, ABL increased the bone strength and BMD of lumbar spine by intermittent administration similar to TPTD.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, abaloparatide had little effect on urine DPD/Cr.

    In plain wordsIn rats with removed ovaries, abaloparatide had little effect on a urine marker of bone breakdown.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeUrine DPD/Cr
    Study

    ratn: not reported in source

    Ovariectomized rats
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both ABL and TPTD increased the bone formation marker serum P1NP with little effect on the bone resorption maker urine DPD/Cr, suggesting anabolic effects on bone.
    1 context sentence
    Summary · context
    In ovariectomized (OVX) rats, ABL increased the bone strength and BMD of lumbar spine by intermittent administration similar to TPTD.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, teriparatide had little effect on urine DPD/Cr.

    In plain wordsIn rats with removed ovaries, teriparatide had little effect on a urine marker of bone breakdown.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeUrine DPD/Cr
    Study

    ratn: not reported in source

    Ovariectomized rats
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both ABL and TPTD increased the bone formation marker serum P1NP with little effect on the bone resorption maker urine DPD/Cr, suggesting anabolic effects on bone.
    1 context sentence
    Summary · context
    In ovariectomized (OVX) rats, ABL increased the bone strength and BMD of lumbar spine by intermittent administration similar to TPTD.
  9. 09LabIn vitro (cells)Mechanism

    In human osteoblastic cells, abaloparatide increased RANKL/OPG expression less than teriparatide under transient treatment.

    In plain wordsIn cells, abaloparatide increased the bone breakdown signal ratio less than teriparatide during brief treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseRANKL/OPG expression under transient treatment
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 hAs given in this study (human).

    Source sentences

    Summary
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  10. 10LabIn vitro (cells)Mechanism

    In human osteoblastic cells, teriparatide increased RANKL/OPG expression more than abaloparatide under transient treatment.

    In plain wordsIn cells, teriparatide increased the bone breakdown signal ratio more than abaloparatide during brief treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRANKL/OPG expression under transient treatment
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 hAs given in this study (human).

    Source sentences

    Summary
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  11. 11LabIn vitro (cells)Mechanism

    In human osteoblastic cells, abaloparatide increased M-CSF expression less than teriparatide under transient treatment.

    In plain wordsIn cells, abaloparatide increased M-CSF expression less than teriparatide during brief treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseM-CSF expression under transient treatment
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 hAs given in this study (human).

    Source sentences

    Summary
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  12. 12LabIn vitro (cells)Mechanism

    In human osteoblastic cells, teriparatide increased M-CSF expression more than abaloparatide under transient treatment.

    In plain wordsIn cells, teriparatide increased M-CSF expression more than abaloparatide during brief treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseM-CSF expression under transient treatment
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 hAs given in this study (human).

    Source sentences

    Summary
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  13. 13LabIn vitro (cells)Mechanism

    In human osteoblastic cells, continuous abaloparatide and teriparatide treatment did not differ significantly in RANKL/OPG expression effects.

    In plain wordsIn cells, continuous abaloparatide and teriparatide treatment had similar effects on the bone breakdown signal ratio.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeRANKL/OPG expression under continuous treatment
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  14. 14LabIn vitro (cells)Mechanism

    In human osteoblastic cells, continuous teriparatide and abaloparatide treatment did not differ significantly in RANKL/OPG expression effects.

    In plain wordsIn cells, continuous teriparatide and abaloparatide treatment had similar effects on the bone breakdown signal ratio.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeRANKL/OPG expression under continuous treatment
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  15. 15LabIn vitro (cells)Mechanism

    In human osteoblastic cells, continuous abaloparatide and teriparatide treatment did not differ significantly in M-CSF expression effects.

    In plain wordsIn cells, continuous abaloparatide and teriparatide treatment had similar effects on M-CSF expression.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeM-CSF expression under continuous treatment
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  16. 16LabIn vitro (cells)Mechanism

    In human osteoblastic cells, continuous teriparatide and abaloparatide treatment did not differ significantly in M-CSF expression effects.

    In plain wordsIn cells, continuous teriparatide and abaloparatide treatment had similar effects on M-CSF expression.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeM-CSF expression under continuous treatment
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  17. 17LabIn vitro (cells)Mechanism

    In human osteoblastic cells, abaloparatide promoted IGF-1 expression similarly to teriparatide.

    In plain wordsIn cells, abaloparatide increased IGF-1 expression similarly to teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeIGF-1 expression
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, ABL and TPTD similarly promoted the expression of bone formation-related factors, IGF-1 and osteocalcin.
    1 context sentence
    Summary · context
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  18. 18LabIn vitro (cells)Mechanism

    In human osteoblastic cells, teriparatide promoted IGF-1 expression similarly to abaloparatide.

    In plain wordsIn cells, teriparatide increased IGF-1 expression similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeIGF-1 expression
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, ABL and TPTD similarly promoted the expression of bone formation-related factors, IGF-1 and osteocalcin.
    1 context sentence
    Summary · context
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  19. 19LabIn vitro (cells)Mechanism

    In human osteoblastic cells, abaloparatide promoted osteocalcin expression similarly to teriparatide.

    In plain wordsIn cells, abaloparatide increased osteocalcin expression similarly to teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeOsteocalcin expression
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, ABL and TPTD similarly promoted the expression of bone formation-related factors, IGF-1 and osteocalcin.
    1 context sentence
    Summary · context
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  20. 20LabIn vitro (cells)Mechanism

    In human osteoblastic cells, teriparatide promoted osteocalcin expression similarly to abaloparatide.

    In plain wordsIn cells, teriparatide increased osteocalcin expression similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeOsteocalcin expression
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, ABL and TPTD similarly promoted the expression of bone formation-related factors, IGF-1 and osteocalcin.
    1 context sentence
    Summary · context
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  21. 21LabIn vitro (cells)Mechanism

    In human osteoblastic cells, abaloparatide and teriparatide did not differ significantly in effects on sclerostin expression.

    In plain wordsIn cells, abaloparatide and teriparatide had similar effects on sclerostin expression.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeSclerostin expression
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, there were no significant differences in the effects on WNT signaling inhibitors such as sclerostin and dickkopf-related protein 1 (DKK1) between the two peptides.
    1 context sentence
    Summary · context
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  22. 22LabIn vitro (cells)Mechanism

    In human osteoblastic cells, teriparatide and abaloparatide did not differ significantly in effects on sclerostin expression.

    In plain wordsIn cells, teriparatide and abaloparatide had similar effects on sclerostin expression.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSclerostin expression
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, there were no significant differences in the effects on WNT signaling inhibitors such as sclerostin and dickkopf-related protein 1 (DKK1) between the two peptides.
    1 context sentence
    Summary · context
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  23. 23LabIn vitro (cells)Mechanism

    In human osteoblastic cells, abaloparatide and teriparatide did not differ significantly in effects on DKK1 expression.

    In plain wordsIn cells, abaloparatide and teriparatide had similar effects on DKK1 expression.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeDKK1 expression
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, there were no significant differences in the effects on WNT signaling inhibitors such as sclerostin and dickkopf-related protein 1 (DKK1) between the two peptides.
    1 context sentence
    Summary · context
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.
  24. 24LabIn vitro (cells)Mechanism

    In human osteoblastic cells, teriparatide and abaloparatide did not differ significantly in effects on DKK1 expression.

    In plain wordsIn cells, teriparatide and abaloparatide had similar effects on DKK1 expression.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeDKK1 expression
    Study

    humann: not reported in source

    Human osteoblastic cells
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, there were no significant differences in the effects on WNT signaling inhibitors such as sclerostin and dickkopf-related protein 1 (DKK1) between the two peptides.
    1 context sentence
    Summary · context
    In human osteoblastic cells, both peptides increased the expression of bone resorption-related factors such as RANKL/OPG and M-CSF, and the effects of ABL were significantly attenuated as compared with those of TPTD under transient 6-h treatment, although no significant differences were found under continuous treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.